Most Popular
QIAGEN N.V. to hold investor call on Wednesday, October 28, after releasing results for...
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced it would hold a conference call on Wednesday, October 28, after releasing full results for the third quarter and first nine months of 2020 on Tuesday, October 27. The call is scheduled for 14:00 Frankfurt time / 13:00 London time / 9:00 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U.S. time switch, the timing of our investor conference call will be held one hour earlier than usual.) Conference call and webcast details: Interested parties may listen to the call by dialing: +1 929 477 0448 (U.S.)+44 (0)330 336 9411 (UK)+49 (0)69 2222 2018 (Germany) Conference ID: 8213322. Please join the conference call about 5-10 minutes prior to the start time. The webcast will be accessible at:https://globalmeet.webcasts.com/starthere.jsp?ei=1394124&tp_key=2f08733c5b A conference call replay will be available by using the following link:https://globalmeet.webcasts.com/starthere.jsp?ei=1394124&tp_key=2f08733c5b Contact: IR@qiagen.com About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies
EU warns not enough Covid-19 vaccines for all in Europe until 2022
BRUSSELS (REUTERS) - Only a share of the European Union population can be inoculated against the new coronavirus before 2022, should an effective vaccine be available, EU officials said in an internal meeting, as governments remain split on vaccination plans. The warning comes in spite of the fact that the 27-nation bloc, with a population of 450 million, has secured more than 1 billion doses of potential Covid-19 vaccines from three drugmakers. It is negotiating the booking of another billion vials with other companies. As a global scramble to secure shots accelerates, experts caution that not every potential vaccine may prove to be effective. "There will not be sufficient doses of Covid-19 vaccines for the entire population before the end of 2021," a European Commission official told diplomats from EU states in a closed-door meeting on Monday, a person who attended it told Reuters. A second official confirmed the statement. An EU Commission spokesman was not immediately available for comment. There is still no effective Covid-19 vaccine, but the first shots could be available at the beginning of next year, the Commission said earlier in October. Related
Global Consortium, Inc., Issues Corporate Update
COCONUT CREEK, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Global Consortium, Inc., (OTCPINK: GCGX) would like to announce major changes taking place within the company. Our Current CEO Matthew Dwyer, is stepping down and will have no further involvement with the Company effective sometime in January of 2021 due to health reasons. The Company has been actively looking for a new CEO to take over in January when Mr. Dwyer steps down. The main concern of potential replacements is that GCGX is not audited. This will need to be addressed prior to anyone willing to assume the position. Over the new next two months GCGX will be working with an accountant who previously worked on getting the 2015-2017 financials of GCGX audited. Since he is familiar with the Company, we hope to have the financials audit ready before the end of the year. The new CEO will oversee the audit and registration of GCGX. In order to get the Company ready for an audit or registration, GCGX needed to take care of some open Corporate issues. GCGX has filed to raise the Authorized with the State of Nevada so that the Series A Preferred can be converted to Common stock.
Harley-Davidson shares soar more than 25 percent after strong quarter
Harley-Davidson beat profit expectations on Tuesday as shipments improved from pandemic lows and it reined in costs as part of Chief Executive Officer Jochen Zeitz’s restructuring plan, sending its shares soaring 26 percent in morning trading. Declines in shipments improved to 6 percent, or 43,000 motorcycles, from a year earlier and compared with a 59 percent slump in the prior quarter, indicating a rise in demand for the maker of large cruisers. Retail sales in its biggest market, the United States, where Harley has not recorded a sales rise for the past six years, fell 10 percent from a year earlier, but was much less than the 27 percent slide in the second quarter. Harley’s sharp recovery from the COVID-19 lows also comes amid Zeitz’s efforts to shut unprofitable markets like India and focus on growth markets such as the US, Europe and parts of Asia-Pacific to lower costs. Total expenses fell 26 percent to $196.9 million in the quarter. In a shift in strategy, Harley announced plans with India’s Hero MotoCorp to develop and sell a range of premium motorcycles under the Harley-Davidson brand name, a month after it discontinued its sales and production in the world’s largest two-wheeler
